ÂÜÀòÂÒÂ×

Brady Burgess is a seasoned scientist with extensive experience in the biopharmaceutical industry. Currently serving as a Senior Scientist at Alector since December 2021, Brady previously held roles at Genentech, including Principal Scientific Researcher and Senior Research Associate, where the focus was on analytical development for therapeutic antibodies. Prior to that, Brady led a group at Eurofins Lancaster Laboratories and contributed to preclinical development at Lypro Biosciences, Inc. Educational qualifications include a Master of Science in Pathology and Laboratory Medicine from The University of British Columbia and a Bachelor of Science in Molecular Biology from Simon Fraser University.